Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Aug. 14, 2014—Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.
Mar. 19, 2014—A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier.
Feb. 3, 2012—Vanderbilt researcher and Gabon, Africa, native is working to discover ways to kill malaria-spreading mosquitoes.
Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.